Save up -80% on Belinostat
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Beleodaq
|$1,875||1 vial/500 mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Belinostat coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your manufacturer copay card in most local pharmacies to get a discount on Belinostat every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Belinostat volume of distribution
The volume of distribution is 409 ± 76.7 L
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Belinostat
PXD101 is a novel investigational small molecule drug that inhibits the enzyme histone deacetylase (HDAC). PXD101 has been shown in preclinical studies to have the potential to treat a wide range of solid and hematologic malignancies either as a monotherapy or in combination with other active agents, and both an oral and intravenous formulation of the drug are being evaluated in clinical trials.
Belinostat mechanism of action
PXD101 is a small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies either as a single-agent, or in combination with other active anti-cancer agents, and is currently being evaluated in a Phase II clinical trial for the treatment of multiple myeloma. HDAC inhibitors represent a new mechanistic class of anti-cancer therapeutics that target HDAC enzymes, and have been shown to: arrest growth of cancer cells (including drug resistant subtypes); induce apoptosis, or programmed cell death; promote differentiation; inhibit angiogenesis; and sensitize cancer cells to overcome drug resistance when used in combination with other anti-cancer agents. PXD101 may block the growth of tumors and the growth of blood vessels from surrounding tissue to the tumor. It may also make tumor cells more sensitive to other anticancer drugs. PXD101 is a type of histone deacetylase (HDAC) inhibitor and angiogenesis inhibitor. Preclinical data showing PXD101 down-regulation of thymidylate synthase (TS), an in vivo target of 5-fluorouracil (5-FU) provide a rationale for combination of PXD101 with 5-FU.
Dosage forms of Belinostat
|Injection, powder, lyophilized, for solution||intravenous||500 mg/10mL|
Spectrum Pharmaceuticals, Inc.
Indication of Belinostat
Belinostat is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with manageable safety profile
Toxicity of Belinostat
Belinostat is genotoxic according to Ames test and may impair male fertility. Weekly complete blood count should be monitored during treatment to adjust the dosage as intravenous infusion of belinostat is frequently associated with hematologic toxicity such as leukopenia and thrombocytopenia. Incidences of infections such as sepsis, hepatotoxicity, tumor lysis syndrome, gastrointestinal toxicity, and embryo-fetal toxicity may occur. No specific information is available on the treatment of overdosage of Beleodaq. There is no antidote for Beleodaq and it is not known if Beleodaq is dialyzable. If an overdose occurs, general supportive measures should be instituted as deemed necessary by the treating physician.
RX24 Drugs Disclaimer: consult your healthcare provider before buying a Belinostat on prescription or using an RX manufacturer savings coupon. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.